The PTAB issued a Final Written Decision in IPR2016-00258, wherein Petitioner Green Cross Corp. challenged claims 1-3, 16, and 17 of Shire Human Genetic Therapies, Inc.’s U.S. Patent No. 9,051,556. Green Cross, which is developing a biobetter of Shire’s Elaprase (idursulfase) for Hunter syndrome, had argued that the challenged claims were…